Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 124

Results For "NIT"

6341 News Found

Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India
News | February 24, 2026

Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India

The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape


FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment
Drug Approval | February 24, 2026

FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment

In 2025, over 1 million patients accessed Lilly treatments through LillyDirect


Sai Life Sciences to hire 700+ professionals to support expansion
News | February 24, 2026

Sai Life Sciences to hire 700+ professionals to support expansion

One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree


Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy
News | February 24, 2026

Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy

The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers


AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi
News | February 24, 2026

AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi

The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands


Novo Nordisk’s
Clinical Trials | February 24, 2026

Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks

UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies


BioVersys’ novel TB drug shows promising results in Phase 2a Trial
Clinical Trials | February 23, 2026

BioVersys’ novel TB drug shows promising results in Phase 2a Trial

The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project


FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL
Drug Approval | February 23, 2026

FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL

The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years


CARE Hospitals positions workforce health as a strategic business imperative at HR Conclave 2026
News | February 23, 2026

CARE Hospitals positions workforce health as a strategic business imperative at HR Conclave 2026

200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities


Dr. Reddy’s secures first-mover advantage with FDA review of Orencia biosimilar
Clinical Trials | February 23, 2026

Dr. Reddy’s secures first-mover advantage with FDA review of Orencia biosimilar

BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data